Harnessing metabolomics and proteomics in a clinical trial for pulmonary arterial hypertension: insights from post-hoc analysis of the REHAB-PH trial - PubMed
7 hours ago
- #PAH
- #proteomics
- #metabolomics
- The study evaluated multi-omic profiles (metabolomics and proteomics) in a clinical trial for pulmonary arterial hypertension (PAH).
- Participants were part of a randomized, placebo-controlled trial of famotidine, with plasma profiling at enrollment and 24 weeks.
- Baseline multi-omic profiles were similar between treatment groups, indicating balanced randomization.
- The placebo group showed high molecular stability over time, while the famotidine group exhibited greater variability.
- Famotidine treatment was associated with significant changes in 191 proteomic pathways, but no significant metabolomic changes after correction.
- The study demonstrated the feasibility of integrating multi-omics in clinical trials to assess molecular responses and biomarker stability.
- Famotidine did not show clinical benefit, but proteomic changes revealed treatment-related biological effects.
- The findings highlight the utility of multi-omics for evaluating drug responses and identifying molecular endotypes in PAH.